Title of the manuscript

Low molecular weight heparin is associated with better outcomes than unfractionated heparin for thromboprophylaxis in hospitalized COVID-19 patients: a meta-analysis

Running head: LMWH vs. UFH in COVID-19 thromboprophylaxis

Authors:

Mochamad Yusuf Alsagaff, Eka Prasetya Budi Mulia, Irma Maghfirah, Yusuf Azmi, Dita Aulia Rachmi, Alqi Yutha, Luqman Hakim Andira, Bambang Pujo Semedi

1. Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Hospital, Surabaya 60132, Indonesia

2. Department of Anesthesiology and Reanimation, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Hospital, Surabaya 60132, Indonesia

Corresponding author:

Mochamad Yusuf Alsagaff, MD., PhD.

Email: yusuf_505@fk.unair.ac.id

Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Hospital, Surabaya 60132, Indonesia

Mayjen Prof. Dr. Moestopo Street No.47

Surabaya 60132, Indonesia

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com
Authors information:

Mochamad Yusuf Alsagaff

Email: yusuf_505@fk.unair.ac.id

Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Hospital, Surabaya 60132, Indonesia

https://orcid.org/0000-0003-2194-6850

Eka Prasetya Budi Mulia

Email: eka.prasetya.budi-2017@fk.unair.ac.id

Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Hospital, Surabaya 60132, Indonesia

https://orcid.org/0000-0002-2681-7743

Irma Maghfirah

Email: irmacardio96@gmail.com

Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Hospital, Surabaya 60132, Indonesia

https://orcid.org/0000-0002-4170-216X

Yusuf Azmi

Email: yusuf.azmi-13@fk.unair.ac.id

Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo General Hospital, Surabaya 60132, Indonesia

https://orcid.org/0000-0001-7841-8149

Dita Aulia Rachmi

Email: dita.aulia.rachmi-2019@fk.unair.ac.id
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga
– Dr. Soetomo General Hospital, Surabaya 60132, Indonesia

https://orcid.org/0000-0003-0741-1542

Alqi Yutha
Email: alqiyutha@gmail.com

Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga
– Dr. Soetomo General Hospital, Surabaya 60132, Indonesia

https://orcid.org/0000-0002-5110-6951

Luqman Hakim Andira
Email: luqman.hakim.a-2020@fk.unair.ac.id

Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga
– Dr. Soetomo General Hospital, Surabaya 60132, Indonesia

https://orcid.org/0000-0002-0954-8772

Bambang Pujo Semedi
Email: bpsemedi@gmail.com

Department of Anesthesiology and Reanimation, Faculty of Medicine, Universitas Airlangga
– Dr. Soetomo General Hospital, Surabaya 60132, Indonesia

https://orcid.org/0000-0001-8829-1540
Abstract

Aims: This study aimed to compare the outcomes of administration of LMWH and UFH in hospitalized COVID-19 patients.

Methods and results: We systematically searched several databases and included observational studies or clinical trials that compared the outcomes of administration of LMWH and UFH in hospitalized COVID-19 patients. A total of nine studies comprising 9637 patients were included. Metanalysis showed that LMWH administration was associated with a lower in-hospital mortality, and 28/30-day mortality compared with UFH administration ([RR 0.44; 95%CI 0.32-0.61; $\text{i}^2$:87.9%] and [RR 0.45; 95%CI 0.24-0.86; $\text{i}^2$:78.4%], respectively). Patient with LMWH had shorter duration of hospital and ICU length of stay compared with UFH ([WMD -2.20; 95%CI -3.01 to -1.40; $\text{i}^2$:0%] and [WMD -1.41; 95%CI -2.20 to -0.63; $\text{i}^2$:0%], respectively). The risk of ICU admission or mechanical ventilation was lower in patients who received LMWH than those who received UFH (RR 0.67; 95%CI 0.55-0.81; $\text{i}^2$:67.3%). However, there was no difference in the incidence of bleeding with LMWH compared with UFH (RR 0.27; 95%CI 0.07-1.01; $\text{i}^2$:64.6%).

Conclusion: Our meta-analysis showed that administration of LMWH was associated with better outcomes compared with UFH in hospitalized COVID-19 patients. Prospective cohorts and RCTs are urgently needed in exploring the definitive effect of LMWH to provide direct high-certainty evidence.

Keywords: COVID-19, low molecular weight heparin, unfractionated heparin, thromboprophylaxis, mortality

PROSPERO registration number: CRD42021271977
Introduction

Coronavirus Disease 2019 (COVID-19) has spread rapidly around the world, causing high morbidity and mortality. Although respiratory symptoms dominate the clinical manifestations of COVID-19, some patients have an increased risk of thromboembolism due to coagulopathy complications. Coagulopathy is one of the severe complications with a high incidence in COVID-19 patients. Elevated coagulation parameters, including D-dimer, prothrombin time, and fibrinogen, are significantly associated with poor prognosis in patients with COVID-19. Activation of the coagulation pathway during the immunologic response to infection may also lead to overproduction of pro-inflammatory cytokines resulting in multiorgan damage.

Early reports demonstrated that anticoagulant thromboprophylaxis was associated with better outcomes in hospitalized COVID-19 patients. Currently, several recommendations suggest venous thromboembolism (VTE) risk stratification and the use of prophylactic anticoagulants in all hospitalized COVID-19 patients. In contrast, evidence is insufficient to support thromboprophylaxis with therapeutic doses of anticoagulants. A meta-analysis showed that anticoagulant regimens in therapeutic and prophylactic doses decreased in-hospital mortality in COVID-19 patients. However, prophylactic doses may be preferred due to the increased risk of bleeding in therapeutic doses of anticoagulants. Another study also demonstrated a similar result that intermediate-to-therapeutic doses of anticoagulant increased mortality and major bleeding compared with prophylactic doses. These findings demonstrate a favourable profile of the efficacy and safety of prophylactic anticoagulation in hospitalized COVID-19 patients.

Although the choice of prophylactic dosing regimen for anticoagulation becomes more evident, the type of anticoagulant itself remains a question. A spectrum of anticoagulants...
such as low molecular weight heparin (LMWH), unfractionated heparin (UFH), fondaparinux, and direct oral anticoagulant (DOAC) are used in the management of COVID-19 patients, with UFH and LMWH as the most commonly prescribed \(^{16}\). A recent study in matched cohorts of COVID-19 patients showed that enoxaparin was associated with lower 28-day mortality compared with UFH \(^{17}\). The plausible superiority of LMWH over UFH was also demonstrated in previous studies with different settings \(^{18-21}\). Therefore, the objective of our systematic review and meta-analysis was to compare the outcomes of administration of LMWH and UFH in hospitalized COVID-19 patients.
Methods

Eligibility criteria

Our analysis included studies that assessed the outcomes of LMWH and UFH administration in hospitalized COVID-19 adult patients. We included articles published in English and studies with extractable data for analysis. Other publications such as case reports, case series, review articles, editorial, and in-vitro or animal studies were excluded. Studies on special populations such as pregnant women and children were also excluded.

Search strategy and study selection

We conducted a systematic literature search based on the search strategy presented in table S1 and finalized the search on June 21, 2022. We searched several databases, including PubMed, ScienceDirect, Scopus, Cochrane Library, and Europe PMC. After eliminating duplication from the literature search, three authors (E.P.B.M., I.M., Y.A.) independently screened the title and abstract. Eligibility criteria were used to assess the full article. The differences in article assessment were solved by a discussion with the senior authors (M.Y.A., B.P.S.). The research protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) database (registration number CRD42021271977). This research followed the recommendations described in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement 22.

Data collection process

Piloted data extraction forms were used independently by three authors (D.A.R., A.Y., L.H.A.) to extract data that consisted of the author, publication date, design of the study, population studied, intervention administered, comparison or control, and outcomes. The comparative intervention assessed in this study was the administration of LMWH and UFH
in hospitalized COVID-19 patients. The primary outcome was in-hospital mortality, while the additional outcomes were 28 or 30-day mortality, intensive care unit (ICU) admission or mechanical ventilation, hospital and ICU length of stay, and bleeding complication. We presented categorical and continuous variables as mean ± standard deviation (SD) and frequency (percentage), respectively.

Quality assessment

All included observational studies were assessed by three authors (E.P.B.M., I.M., Y.A.) independently using the Newcastle-Ottawa score (NOS), which consisted of three domains that include sample selection, comparability of cohorts, and outcomes assessment. The risk of bias for the included randomized controlled trial (RCT) was assessed by the modified Cochrane Collaboration tool. Discussions were held to resolve the discrepancies between authors.

Data analysis

Data used for each included study was following univariate analysis in the original study. Pooled effect estimates of the outcomes were reported as weighted mean difference (WMD) and relative risk (RR) for the continuous and dichotomous variables, respectively. Data with low heterogeneity (I² statistic <50% or P-value > 0.1) were pooled with a fixed-effects model, and data with high heterogeneity (I² statistic >50% or P-value < 0.1) were pooled with a random-effects model. P-value < 0.05 was determined as statistical significance. We used funnel-plot analysis to assess the publication bias qualitatively. Egger's test and Harbord's test were used to further assessed publication bias on continuous and dichotomous variables, respectively. Furthermore, univariate meta-regression analysis was performed to determine which factors contributed to in-hospital mortality in hospitalized
COVID-19 patients receiving two different anticoagulants of LMWH and UFH. Meta-analysis was performed on Stata software V.14.0 (College Station).

**Results**

**Study characteristics**

We identified 6243 articles from the initial database search and 2 articles through additional search and then removed the duplicates. The remaining 4701 articles were screened for titles and abstracts, which resulted in 4406 articles being excluded. Using the eligibility criteria, 295 potential full-text articles were assessed. Finally, seven observational studies and two RCTs consisting of 9637 patients were included for qualitative analysis and meta-analysis (Figure 1 and Table 1).

**Outcome comparison between low molecular weight heparin and unfractionated heparin**

The meta-analysis showed that LMWH administration was associated with a lower risk of in-hospital mortality compared with UFH administration (relative risk, RR 0.44; 95%CI 0.32-0.61; $I^2$:87.9%) and [RR 0.45; 95%CI 0.24-0.86; $I^2$:78.4%], respectively). These effects were comparable to the pooled risk estimates comprising both doses of therapeutic and prophylactic (RR 0.28; 95% CI 0.17-0.47; P = 0.001; $I^2$:86.3%) and solely prophylactic doses (RR 0.63; 95% CI 0.46-0.87; P = 0.005; $I^2$:65.6%) (Figure 2). Similar results were obtained at one month follow-up that LMWH was associated with a lower 28 or 30-day mortality compared with UFH (RR 0.45; 95%CI 0.24-0.86; $I^2$:78.4%) (Figure 2).

Patient who received therapeutic and prophylactic doses of LMWH had shorter duration of hospital and ICU length of stay than those who received therapeutic and prophylactic doses of UFH (weighted mean difference, WMD -2.20; 95% CI -3.01 to -1.40; P < 0.001; $I^2$:0%) and [WMD -1.41; 95% CI -2.20 to -0.63; P < 0.001; $I^2$:0%], respectively) (Figure 3). The risk of ICU
admission or mechanical ventilation was also lower in patients who received LMWH than those who received UFH (RR 0.67; 95% CI 0.55-0.81; P = 0.016; I²: 67.3%) (Figure 4). However, there was no significant difference in the incidence of bleeding with LMWH compared with UFH (RR 0.27; 95% CI 0.07-1.01; P = 0.052; I²: 64.6%) (Figure S1).

Meta-regression

Univariate meta-regression analysis revealed that the association of two different anticoagulants of LMWH and UFH with in-hospital mortality in COVID-19 patients was not significantly affected by age (P = 0.463), gender (P = 0.954), hypertension (P = 0.571), diabetes (P = 0.912), chronic kidney disease (P = 0.597), cancer (P = 0.802), chronic lung disease (P = 0.604), heart failure (P = 0.812), coronary artery disease (P = 0.901), asthma (P = 0.742), chronic liver disease (P = 0.358), and stroke and cerebrovascular disease (P = 0.398) (Table S2).

Quality assessment and publication bias

Seven studies were of high quality based on the assessment using NOS (Table S3), and two RCTs showed a low overall risk of bias based on the assessment using the modified Cochrane Collaboration tool (Table S4). The asymmetric shape was obtained by visually qualitative assessment of the funnel plot for analysis on the variables of anticoagulant selection and mortality, indicating possible publication bias (Figure S2). However, quantitative analysis using regression-based Harbord's test showed no small-study effects (p = 0.876) on the same variable.

GRADE assessment

Grading of Recommendations Assessment, Development, and Evaluation (GRADE) assessment indicated a very low certainty of the evidence for the effect of LWMH and UFH on in-hospital mortality, 28 or 30-day mortality, hospital and ICU length of stay, ICU
admission or mechanical ventilation, and bleeding complication. The certainty of the evidence was very low for both subgroups of in-hospital mortality outcomes (Table S5).

Discussion

This systematic review and meta-analysis highlighted the differences in outcomes associated with the administration of LMWH and UFH in hospitalized COVID-19 patients. We found that LMWH was associated with lower in-hospital mortality, 28 or 30-day mortality, ICU admission or mechanical ventilation, and bleeding complication compared with UFH. Furthermore, we found that patients treated with LMWH had a shorter hospital and ICU length of stay compared with those treated with UFH.

A spectrum of anticoagulants, including LMWH, UFH, fondaparinux, and DOAC, are used in managing COVID-19 patients, both as prophylactic and therapeutic approaches. Heparin is one of the anticoagulant drugs that is classified according to its molecular weight and is used for the prophylaxis and treatment of venous and arterial thrombosis. Only UFH comprising at least 18 saccharide sequences can bind to and potentiates the activity of antithrombin. However, UFH of any length comprising a unique pentasaccharide sequence can inhibit the action of factor Xa. This pentasaccharide sequence is used as the basis for developing LMWH. In contrast to UFH, whose main action is mediated by thrombin inhibition, LMWH inhibits prothrombin activation more robustly through its action on factor Xa.

The proposed mechanisms of using heparin in COVID-19 management are to block uncontrolled blood clotting and prevent VTE and other thrombotic events. However, heparin may also offer anti-inflammatory, anti-complement activity, anti-viral, and immunomodulatory effects, which may benefit beyond the anticoagulation in COVID-19.
Recent studies have also reported that soluble heparin inhibited viral entry by competing with heparan sulfate proteoglycan for binding to the SARS-CoV-2 spike protein, thereby inhibiting the attachment of SARS-CoV-2 to the surface of the host cell.

The superiority of LMWH over UFH has been demonstrated by previous studies in several different settings. A meta-analysis of RCTs comparing the administration of anticoagulant thromboprophylaxis in intensive care patients showed that LMWH was associated with a better net clinical benefit and a lower risk of DVT compared with UFH. Another meta-analysis of patients with VTE showed that compared with UFH, initial treatment with LMWH was more effective in preventing recurrent VTE, reduced the risk of bleeding, and was associated with a lower mortality rate at follow-up. In addition, the incidence of pulmonary embolism and proximal DVT was lower in patients undergoing orthopedic surgery who received LWMH than UFH.

There are several reasons that explain the plausible superiority of LMWH over UFH. Heparin-induced thrombocytopenia (HIT) is less common with LMWH than with UFH. A meta-analysis evaluating the incidence of HIT in patients at risk for VTE treated with prophylactic doses of anticoagulant showed that the incidence of HIT was lower with LMWH (0.2%) than with UFH (2.6%). The peak anti-Xa activity (Cmax) and area under the curve (AUC) are higher with enoxaparin and dalteparin compared with UFH. In addition, administration of heparin increases the release of TPFI antigen, an inhibitor of tissue factor that plays a role in the antithrombotic effect of heparin. However, unlike UFH, the LMWH administration can increase TPFI that lasts longer in circulation. This finding may explain the different antithrombotic efficacy of LMWH and UFH in clinical settings. LMWH is also better than UFH at suppressing inflammatory tissue factor expression and contributes to endothelial hemostatic properties in the microvasculature, where endothelial dysfunction is
associated with poor outcomes in COVID-19 patients. Finally, LMWH is preferred over UFH because of its good predictability, dose-dependent plasma levels, and longer plasma half-life, allowing it to be administered subcutaneously once or twice daily and reducing healthcare worker exposure.

**Clinical implication**

Our meta-analysis suggests that LMWH may provide better outcomes in COVID-19 patients. These results may provide evidence for the current recommendation that LMWH is preferred over UFH as thromboprophylaxis for COVID-19. However, this new evidence does not justify changing existing guidelines and is insufficient to support or oppose using UFH as thromboprophylaxis in hospitalized COVID-19 patients. Currently, the selection of anticoagulant agents may still be based on the availability of anticoagulants, the experience of the physicians, treatment objectives, and other patient-specific factors. Further evidence from RCTs is urgently needed to determine the most effective anticoagulant agents for thromboprophylaxis in COVID-19 patients.

**Limitations**

There are several limitations to this meta-analysis. Possible publication bias was noted in several outcomes, as well as substantial heterogeneity. Most of the included studies were retrospective observational, which were not matched or adjusted for confounders, so the strength of the association could not be measured accurately. The dose definition of the prophylactic or therapeutic LMWH or UFH, including the route of administration, also varied slightly across studies. Another issue is that the presence of both prophylactic and therapeutic dosing in the studies included outcome, especially in noncritically ill COVID-19 patients, as shown in the recent studies. Some studies did not mention the specific type of LMWH, and not all studies provide details regarding the selection criteria for LMWH or
UFH (reason for using LMWH or UFH at an individual level cannot be identified), such as the use of UFH, which is the preferred choice for patients with renal dysfunction or disseminated intravascular coagulation. These problems may translate into uncertain effect estimates from these individual studies. Most studies also did not mention pre-existing conditions that have been anticoagulated before admission. The definition of bleeding also varied across studies. Lastly, one study by Lopes et al. only included hospitalized adult patients with elevated D-dimer levels.

Conclusion
Our meta-analysis highlighted current evidence that administration of LMWH was associated with better outcomes compared with UFH in hospitalized COVID-19 patients. Nevertheless, this meta-analysis does not provide guidance for therapeutic decision-making or changing the existing guidelines for COVID-19 thromboprophylaxis. Until direct high-certainty evidence comparing these two types of anticoagulants is available, clinical inference from this analysis should be drawn with caution. Prospective cohorts and RCTs are urgently needed in exploring the definitive effect of LMWH and UFH to provide direct high-certainty evidence.

Disclosure statement

Funding statement
None.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article. The corresponding author (A) can be contacted for more information.

**Credit authorship contribution statement**

M.Y.A. and B.P.S. contributed to the study conception and design. E.P.B.M., I.M., and Y.A. performed article screening and quality assessment of the studies. D.A.R., A.Y., and L.H.A. performed literature retrieval and data extraction. E.P.B.M. and Y.A wrote the first draft of the manuscript. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

**Declaration of competing interest**

The authors declared no conflict of interest.

**Acknowledgments**

None.
References

1. Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and Cardiovascular Disease. 
   *Circulation*. 2020;141:1648-1655. doi:10.1161/CIRCULATIONAHA.120.046941

2. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. *Nat Rev Cardiol*. 2020;17(5):259-260. doi:10.1038/s41569-020-0360-5

3. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res*. 2020;191:145-147. doi:10.1016/j.thromres.2020.04.013

4. Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. *Intensive Care Med*. 2020;46(6):1089-1098. doi:10.1007/s00134-020-06062-x

5. Polimeni A, Leo I, Spaccarotella C, et al. Differences in coagulopathy indices in patients with severe versus non-severe COVID-19: a meta-analysis of 35 studies and 6427 patients. *Sci Rep*. 2021;11(1):10464. doi:10.1038/s41598-021-89967-x

6. Nugroho J, Wardhana A, Mulia EP, et al. Elevated fibrinogen and fibrin degradation product are associated with poor outcome in COVID-19 patients: A meta-analysis. *Clin Hemorheol Microcirc*. 2021;77(2):221-231. doi:10.3233/CH-200978

7. Nugroho J, Wardhana A, Maghfirah I, et al. Relationship of D-dimer with severity and mortality in SARS-CoV-2 patients: A meta-analysis. *Int J Lab Hematol*. 2021;43(1):110-115. doi:10.1111/ijlh.13336

8. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. *Lancet Respir Med*. 2020;8(6):e46-e47. doi:10.1016/S2213-2600(20)30216-2

9. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with
decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemost*. 2020;18(5):1094-1099. doi:10.1111/jth.14817

10. Rentsch CT, Beckman JA, Tomlinson L, et al. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: Cohort study. *BMJ*. 2021;372. doi:10.1136/bmj.n311

11. Cuker A, Tseng EK, Nieuwlaat R, et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. *Blood Adv*. 2021;5(3):872-888. doi:10.1182/bloodadvances.2020003763

12. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. *J Thromb Haemost*. 2020;18(5):1023-1026. doi:10.1111/jth.14810

13. Marietta M, Ageno W, Artoni A, et al. COVID-19 and haemostasis: A position paper from Italian Society on Thrombosis and Haemostasis (SISET). *Blood Transfus*. 2020;18(3):167-169. doi:10.2450/2020.0083-20

14. Parisi R, Costanzo S, Di Castelnuovo A, De Gaetano G, Donati MB, Iacoviello L. Different Anticoagulant Regimens, Mortality, and Bleeding in Hospitalized Patients with COVID-19: A Systematic Review and an Updated Meta-Analysis. *Semin Thromb Hemost*. 2021;47(4):372-391. doi:10.1055/s-0041-1726034

15. Moonla C, Sosothikul D, Chiasakul T, Rojnuckarin P, Uaprasert N. Anticoagulation and In-Hospital Mortality From Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. *Clin Appl Thromb*. 2021;27. doi:10.1177/10760296211008999

16. Chandra A, Chakraborty U, Ghosh S, Dasgupta S. Anticoagulation in COVID-19: Current concepts and controversies. *Postgrad Med J*. 2021;0:1-8.
17. Pawlowski C, Venkatakrishnan AJ, Kirkup C, et al. Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients. *EclinicalMedicine*. 2021;33. doi:10.1016/j.eclinm.2021.100774

18. Jacobs BN, Cain-Nielsen AH, Jakubus JL, et al. Unfractionated heparin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in trauma. *J Trauma Acute Care Surg*. 2017;83(1):151-158. doi:10.1097/TA.0000000000001494

19. Erkens PMG, Prins MH. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. *Cochrane Database Syst Rev*. 2010;(9). doi:10.1002/14651858.CD001100.pub3

20. Koch A, Ziegler S, Breitschwerdt H, Victor N. Low Molecular Weight Heparin and Unfractionated Heparin in Thrombosis Prophylaxis: Meta-Analysis Based on Original Patient Data. *Thromb Res*. 2001;102(4):295-309. doi:https://doi.org/10.1016/S0049-3848(01)00251-1

21. Beitland S, Sandven I, Kjærvik L-K, Sandset PM, Sunde K, Eken T. Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis. *Intensive Care Med*. 2015;41(7):1209-1219. doi:10.1007/s00134-015-3840-z

22. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med*. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097

23. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol*. 2010;25(9):603-605.
24. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. *Bmj*. 2011;343.

25. Gil MR, Gonzalez-Lugo JD, Rahman S, et al. Correlation of coagulation parameters with clinical outcomes during the Coronavirus-19 surge in New York: Observational cohort. *Front Physiol*. 2021;12.

26. Kirkup C, Pawlowski C, Puranik A, et al. Healthcare disparities among anticoagulation therapies for severe COVID-19 patients in the multi-site VIRUS registry. *J Med Virol*. 2021;93(7):4303-4318. doi:10.1002/jmv.26918

27. Nadkarni GN, Lala A, Bagiella E, et al. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. *J Am Coll Cardiol*. 2020;76(16):1815-1826.

28. Piazza G, Campia U, Hurwitz S, et al. Registry of arterial and venous thromboembolic complications in patients with COVID-19. *J Am Coll Cardiol*. 2020;76(18):2060-2072.

29. Volteas P, Drakos P, Alkadaa LN, et al. Low-Molecular-Weight Heparin Compared to Unfractionated Heparin in Critically Ill COVID-19 Patients. *J Vasc Surg Venous Lymphat Disord*. 2022;0(0). doi:10.1016/j.jvsv.2022.04.019

30. Lopes RD, de Barros E Silva PGM, Furtado RHM, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. *Lancet (London, England)*. 2021;397(10291):2253-2263. doi:10.1016/S0140-6736(21)01203-4

31. Oliynyk O, Barg W, Slifirczyk A, et al. Comparison of the Effect of Unfractionated Heparin and Enoxaparin Sodium at Different Doses on the Course of COVID-19-Associated Coagulopathy. *Life*. 2021;11(10):1032. doi:10.3390/life11101032
32. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. *Blood*. 2020;135(23):2033-2040. doi:10.1182/blood.2020006000

33. Hirsh J, Anand SS, Halperin JL, Fuster V. Guide to Anticoagulant Therapy: Heparin. *Circulation*. 2001;103(24):2994-3018. doi:10.1161/01.CIR.103.24.2994

34. Costanzo L, Palumbo FP, Ardita G, et al. Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia. *J Vasc surgery Venous Lymphat Disord*. 2020;8(5):711-716. doi:10.1016/j.jvsv.2020.05.018

35. Newall F. Anti-factor Xa (Anti-Xa) Assay BT - Haemostasis: Methods and Protocols. In: Monagle P, ed. Totowa, NJ: Humana Press; 2013:265-272. doi:10.1007/978-1-62703-339-8_19

36. Tiwari NR, Khatib KI, Dixit SB, et al. Anticoagulation in COVID-19: An Update. *J Crit care Med (Universitatea Med si Farm din Targu-Mures)*. 2020;6(4):217-223. doi:10.2478/jccm-2020-0033

37. Gozzo L, Viale P, Longo L, Vitale DC, Drago F. The potential role of heparin in patients with COVID-19: beyond the anticoagulant effect. A review. *Front Pharmacol*. 2020;11.

38. Shi C, Tingting W, Li J-P, et al. Comprehensive landscape of heparin therapy for COVID-19. *Carbohydr Polym*. 2020;117232.

39. Martel N, Wells PS. A Meta-Analysis to Determine the Risk of Heparin Induced Thrombocytopenia (HIT) and Isolated Thrombocytopenia in Prophylaxis Studies Comparing Unfractionated Heparin (UFH) and Low Molecular Weight Heparin (LMWH). *Blood*. 2004;104(11):2587. doi:10.1182/blood.V104.11.2587.2587

40. Eriksson BI, Söderberg K, Widlund L, Wandeli B, Tengborn L, Risberg B. A Comparative Study of Three Low-molecular Weight Heparins (LMWH) and Unfractionated Heparin (UH) in Healthy Volunteers. *Thromb Haemost*. 1995;73(03):398-401.
41. Hansen J-B, Sandset PM, Huseby KR, et al. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action. *Br J Haematol.* 1998;101(4):638-646. doi:https://doi.org/10.1046/j.1365-2141.1998.00770.x

42. A Vignoli, M Marchetti, D Balducci, T Barbui, A Falanga. Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties. *Haematologica.* 2006;91(2 SE-Comparative Studies):207-214. doi:10.3324/hae.2006.5383

43. Andrianto, Al-Farabi MJ, Nugraha RA, Marsudi BA, Azmi Y. Biomarkers of endothelial dysfunction and outcomes in coronavirus disease 2019 (COVID-19) patients: A systematic review and meta-analysis. *Microvasc Res.* 2021;138:104224. doi:https://doi.org/10.1016/j.mvr.2021.104224

44. Moores LK, Tritschler T, Brosnahan S, et al. Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report. *Chest.* 2020;158(3):1143-1163. doi:10.1016/j.chest.2020.05.559

45. Spyropoulos AC, Levy JH, Ageno W, et al. Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. *J Thromb Haemost.* 2020;18(8):1859-1865. doi:10.1111/jth.14929

46. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. *N Engl J Med.* 2021;385(9):790-802. doi:10.1056/NEJMoa2105911

47. Sholzberg M, Tang GH, Rahhal H, et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID
randomised clinical trial. Laupacis A, Lin Y, Day A, et al., eds. BMJ. 2021;375.

doi:10.1136/bmj.n2400
### Table 1. Characteristics of included studies.

| No | Author, year | Study design | Population | Setting | Time period | Prophylactic doses | Therapeutic doses | Outcome extracted | Bleeding definition | N | Age, year | Male, % | HTN | DM | CKD | Cancer | Quality |
|----|--------------|--------------|------------|---------|-------------|-------------------|------------------|------------------|-------------------|---|----------|---------|------|-----|------|--------|---------|
| 1  | Volteas, 2022 | Retrospective | Critically ill intubated adult patients | Stony Brook University Hospital | February 7 - May 17, 2020 | Enoxaparin: 40 mg daily (D-dimer <1,000 ng/mL) or 40 mg twice a day (D-dimer ≥ 1,000 ng/mL) | Enoxaparin: 1 mg/kg twice a day or UFH: IV starting rate of 18 units/kg/hr to achieve a goal PTT of 60 to 90 | Mortality | NA | 240 (LMWH proph: 70; ther: 65; UFH proph: 11; ther: 72) | ≥ 18 | NA | NA | NA | NA | NA | 7 |
| 2  | Oliynyk, 2021 | Randomized control trial single center | Severe hospitalized adult patients | Kyiv City Clinical Hospital No.4 | July 1, 2020 - March 1, 2021 | Enoxaparin: 50 anti-Xa IU/kg SC QD | Enoxaparin: 100 anti-Xa IU/kg SC BID; UFH: IV initial 80 U/kg/h, followed by 18 U/kg/h with APTT of 40–70 s | 28-day mortality, mechanical ventilation | NA | 126 (LMWH proph: 42; ther: 42; UFH ther: 42) | 70.3 ± 2.8 | 60.3 | NA | NA | NA | NA | Low over all risk of bias |
| 3  | Gil, 2021 | Retrospective | Hospitalized adult patients | Tertiary care center | March 20 - March 31, 2020 | Enoxaparin: 40 mg SC once a day (BMI<40, GFR=30) or 30 mg SC twice a day (BMI=40); UFH: NA | Enoxaparin: 1.5 mg/kg/day or 1 mg/kg twice a day; UFH: 80 units/kg/JV followed by continuous IV infusion | Mortality | NA | 225 (LMWH proph: 127, ther: 4; UFH proph: 20; ther: 10) | 62.1 ± 14.4 | 57.8 | 64.9 | 38.7 | 19.1 | 8.4 | 8 |
| 4  | Kirkup, 2021 | Retrospective multicenter | Hospitalized adult patients | 192 hospitals in 20 countries | Start time NA – January 4, 2021 | NA | NA | Mortality, 28-day mortality, ICU admission, length of stay | NA | 3196 (LMWH: 1939; UFH: 1012) | 63.6 ± 28.2 | 57.1 | 54.0 | 34.9 | 12.8 | 6.7 | 9 |
| 5  | Lopes, 2021 | Randomized Hospitalization | 31 | June 24, 2021 | Enoxaparin: 40 | Enoxaparin: 1 | Mortality, Major | 615 | 56.6 | 59.8 | 49.1 | 24.4 | NA | 0 | Low |
| Study Year | Study Type | Setting | Number of Patients | Start Date - End Date | Enoxaparin Dose | UFH Dose | Patient Characteristics | End Points | Mortality | Major Bleeding | Other Outcomes | Bias Risk |
|------------|------------|---------|--------------------|----------------------|-----------------|---------|------------------------|------------|-----------|---------------|--------------|-----------|
| 2021       | Control multicenter | Hospitals in Brazil  | 2020 - February 26, 2021 | mg QD SC (GFR≥30, BMI<40), 60 mg QD SC or 40 mg BID SC (GFR≥30, BMI≥40); UFH: 5000 units TID/BID SC (BMI<40), 7500 units TID/BID SC (BMI≥40) | mg/kg BID SC or 1.5 QD SC mg/kg (GFR≥30, BMI≥40), 0.75 mg/kg BID SC (GFR≥30, BMI<40, age≥75), 1 mg/kg BID SC (GFR≥30, BMI<40), 1 mg/kg QD SC (GFR<30, BMI<40); UFH: 60 unit/kg IV bolus, then 12 units/kg/hr | bleeding / ISTH criteria | (LMWH: 256; UFH: 47) | ± 14.3 | over all risk of bias |
| Nadkarni, 2020 | Retrospective multicenter | New York City hospitals | March 1 - April 3, 2020 | Enoxaparin: 1 mg/kg twice daily or 1.5 mg/kg daily; UFH: continuous IV infusions | Mortality, mechanical ventilation, major bleeding | Major bleeding by ICD 10th Revision codes | 2859 (LMWH: 445; UFH: 941) | 66.5 ± 16.2 |
| Pawlowski, 2020 | Retrospective multicenter | Mayo Clinic sites in Arizona, Florida, Minnesota, and Wisconsin | April 4 - August 31, 2020 | Enoxaparin: ≤ 40mg/day SC; UFH: periodic administration | Mortality, 28-day mortality, ICU admission, length of stay, bleeding | Bleeding complications from the physician notes | 557 (LMWH: 441; UFH: 166) | 58.4 ± 17.9 |
| Piazza, 2020 | Retrospective multicenter | The Mass General Brigham integrated health network | March 13 - April 3, 2020 | NA | ICU admission | NA | 399 (LMWH: 277; UFH: 102) | 61.1 ± 17.1 |
| Rentsch, 2020 | Retrospective multicenter | > 1200 points of care | March 1 - July 31, 2020 | Enoxaparin: 40 mg QD or 30 mg BID SC; UFH: IV dose | Mortality, 30-day mortality | NA | 3627 (LMWH: 2506; UFH: 936) | ± 12.3 |
| Hospital | Nationwide of US Department of Veterans Affairs |
|----------|-----------------------------------------------|
| 5000 units BID or TID SC | adjusted on PTT |

UFH: 1094)

N = number of samples; UFH = unfractionated heparin; HTN = hypertension; DM = diabetes mellitus; CKD = chronic kidney disease; BMI = body mass index, GFR = glomerular filtration rate; NA = not available; QD = *quaque die* means once a day; BID = *bis in die* means twice a day; TID = *ter in die* means three times a day; IV = intravenous; SC = subcutaneous; ICU = intensive care unit; ISTH = International Society on Thrombosis and Haemostasis; proph: prophylactic, ther: therapeutic.
**Figure 1.** PRISMA flowchart.
**Figure 2.** Panel A: forest plot for the association of two different types of anticoagulant (LMWH vs UFH) with in-hospital mortality in hospitalized COVID-19 patients. Panel B: forest plot for the association of two different types of anticoagulant (LMWH vs UFH) with 28 or 30-day mortality in COVID-19 patients.
Figure 3. Panel A: forest plot for the association of two different types of anticoagulant (LMWH vs UFH) with hospital length of stay in COVID-19 patients. Panel B: forest plot for the association of two different types of anticoagulant (LMWH vs UFH) with ICU length of stay in COVID-19 patients.
**Figure 4.** Forest plot for the association of two different types of anticoagulant (LMWH vs UFH) with ICU admission or mechanical ventilation in all hospitalized COVID-19 patients.